42 results about "Rifampicin" patented technology

The invention discloses a primer composition for detecting drug resistance of mycobacterium tuberculosis, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at an rpoB gene, a primer pair aiming at a katG gene, a primer pair aiming at an inhA gene, a primer pair aiming at an ahpC gene, a primer pair aiming at a gyrA gene and a primer pair aiming at a gyrB gene. According to the invention, mutation of mycobacterium tuberculosis complex and rifampicin, isoniazide and quinolone drug resistance related genes rpoB, katG, inhA, ahpC, gyrA and gyrB genes in sputum of a tuberculosis patient can be detected at one time, single-tube multiple high-sensitivity detection is realized, wild genes and mutant genes are accurately distinguished, and serious cross reaction is avoided.

The invention discloses a wrapping material for implantable electronic equipment and a preparation method of the wrapping material. The wrapping material comprises a degradable polymer base material with a porous structure and a drug-loaded slow-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array mode, the holes are circular, the hole diameter is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm. According to the wrapping material disclosed by the invention, the degradable polymer is taken as a base material, and the drug-loading coating containing rifampicin and minocycline hydrochloride is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the wrapping material has excellent antibacterial performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal faced by the implantable electronic equipment for a long time are solved.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially / fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

The application provides a primer probe set and a kit for detecting a rifampicin-resistant gene of Mycobacterium tuberculosis, and belongs to the technical field of molecular biology detection.The primer probe set comprises RAA primers and qPCR primers targeting the rpoB gene, probe primers targeting the wild-type rpoB gene, and probe primers targeting the mutant rpoB gene.The application adopts the detection methods of RT-RAA and qPCR in sequence, and the above specific primer probe set can be combined to simultaneously and rapidly detect the 516, 526, 531 and 533 sites of the rpoB gene of Mycobacterium tuberculosis, has good specificity, and the detection sensitivity can reach 5 copies / ul, is 20 times higher than the sensitivity of qPCR (100 copies / ul), and has a 5% detection capability for heterogenic drug resistance mutation; the detection method can also greatly shorten the detection time.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

The invention discloses a method for constructing a genetic transformation system of cymbidium kanran, which belongs to the technical field of plant genetic engineering, and comprises the following steps of: carrying out monoclonal propagation on rhizomes after germination of cymbidium kanran seeds to obtain vegetative propagules with stable characters, taking the vegetative propagules as transformation receptors, taking GFP (Green Fluorescent Protein) as marker genes, and constructing the genetic transformation system of cymbidium kanran. The method comprises the following steps: adding agrobacterium EHA105 into a YEB liquid culture medium containing 50 mg / L of kanamycin and 25 mg / L of rifampicin as a dip dyeing solution; placing the injured transformation receptor in dip dyeing for transformation, and then carrying out regeneration culture. The invention relates to a method for carrying out genetic transformation on cymbidium kanran by utilizing the innovative receptor and the screening culture medium, and the method can realize efficient and stable genetic transformation without genotype dependence and can solve the problem that the genetic transformation of cymbidium kanran varieties is difficult to carry out. According to the invention, an efficient genetic transformation and regeneration system of cymbidium kanran is established for the first time, and a foundation is laid for verification of related functional genes of cymbidium kanran and further development of biological research of cymbidium transgenic breeding and the like.

The invention discloses a fixing material for a medical device implant and a preparation method of the fixing material. The fixing material comprises a degradable polymer base material with a porous structure and a drug sustained-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array manner, the holes are circular, the aperture of each hole is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm; the drug sustained-release coating contains antibiotics; the antibiotics comprise rifampicin, minocycline hydrochloride, vancomycin, tobramycin, gentamicin and the like. The fixing material disclosed by the invention takes the degradable polymer as a base material, and the drug-loading coating containing antibiotics and anti-inflammatory substances is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the fixing material has excellent antibacterial and anti-inflammatory performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal of the implant for a long time are solved.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

This invention belongs to the field of electroluminescence technology, specifically relating to a method for preparing a high-entropy MOF material and its application in the electrochemiluminescence detection of rifampicin. The high-entropy MOF material is a pentagonal high-entropy MOF material (HE-ATA) synthesized from metal nitrates of Fe, Co, Cu, Cr, and Zn and ATA as raw materials. This invention yields a HE-ATA catalyst with simple raw materials, convenient synthesis, and excellent electrochemiluminescence performance. It exhibits chemical stability and a multi-electron reaction potential that accelerates the conversion of dissolved oxygen to reactive oxygen species (ROS), enhancing the electroluminescence intensity. Based on the quenching effect of RIF, a method for detecting RIF using a luminol / HE-ATA system was established. By fitting the change in ECL intensity with RIF concentration, a linear calibration curve with a correlation coefficient of 0.996 and a detection limit of 3.3 × 10⁻⁶ was obtained. ‑6 µM (S / N=3). This material exhibits good sensitivity, stability, and reproducibility in the electrochemiluminescence detection of RIFs, providing a new approach for designing novel electrocatalysts for RIF detection.

This invention relates to a compound antibacterial agent and its application in open plant tissue culture. The active ingredients of the compound antibacterial agent include rifampin, kasugamycin, ticarcillin sodium clavulanic acid, and tetrachloroisophthalonitrile. The compound antibacterial agent can synergistically inhibit Agrobacterium rhizogenes or Rhodotorula glutinis, contaminating bacteria that are easily generated during plant tissue culture.

The invention belongs to the technical field of biomedical nano-materials, and particularly relates to a preparation method and application of responsive nano-particles for targeted removal of fusobacterium nucleatum and a biological membrane of the fusobacterium nucleatum. The ERPNPs is formed by self-assembly of PEG (polyethylene glycol)-b-PCL (polycaprolactone), Pep-PAE (polycaprolactone)-b-PCL (polycaprolactone) and (PBA / PAE)-b-PCL, and the ERPNPs carry rifampicin and gallocatechin gallate together. The nano-system exposes FadA target peptide in an acidic tumor microenvironment, accurately recognizes Fn and synergistically sterilizes and disperses a biological membrane, so that an immunosuppression microenvironment is reversed, and the nano-system has an important application prospect in the development of anti-CRC drugs.

The application belongs to the technical field of biomedicine, and discloses a method for constructing a Channa argus bile stasis model. The application discloses application of rifampicin or a pharmaceutically acceptable salt thereof in construction of a fish liver injury model. The application discloses, for the first time, that the antibiotic rifampicin widely used in aquaculture is used to construct a fish liver injury model. The model is closer to the real scene of the use of a large amount of drugs when bacterial diseases break out in production practice. The injury type of the fish liver injury model is clearly directed to bile stasis, which fills the research blank of the disease model of the fish, and is different from common hepatocyte necrosis or fatty liver models.

The invention discloses a crRNA combination for detecting mycobacterium tuberculosis and a drug-resistant mutation site thereof, a kit and application, and belongs to the technical field of molecular detection. The crRNA combination comprises a crRNA-MTB (Complementary Ribonucleic Acid-Methyl Terminals B) used for detecting the mycobacterium tuberculosis, a crRNA-MTB-rpoB used for detecting the rifampicin drug-resistant mutation site of the mycobacterium tuberculosis, and a crRNA-MTB-katG used for detecting the isoniazide drug-resistant mutation site of the mycobacterium tuberculosis; by designing the specific crRNA combination for detecting the mycobacterium tuberculosis and the drug-resistant mutation site thereof, the sensitivity of detecting the mycobacterium tuberculosis and the drug-resistant mutation site thereof can be remarkably improved, the detection time can be shortened, and synchronous detection of the mycobacterium tuberculosis and the drug-resistant mutation site thereof can be realized, so that the kit has the advantages that the detection sensitivity is greatly improved, and the detection time is shortened. The method has a good application prospect in detection of the mycobacterium tuberculosis and the drug-resistant mutation site of the mycobacterium tuberculosis.

The invention provides a reaction system for detecting mycobacterium tuberculosis and rifampicin drug resistance genes thereof. The reaction system comprises DNA polymerase, dNTPs, a reaction buffer solution and a primer for amplifying a template, the reaction system comprises magnesium ions, disodium hydrogen phosphate and a double-strand displacement probe composition, the reaction system can be combined with the double-strand displacement probe composition through synergy of the magnesium ions and the disodium hydrogen phosphate, and the defects that according to a conventional melting curve method, the number of impure peaks is large, the peak heights of melting curves are inconsistent under the same condition, and the sensitivity of the melting curves is low can be overcome; the method has the advantages of low fluorescence background, high detection sensitivity, good specificity and good stability, the purpose of multiple analysis of rifampicin sensitivity and drug resistance in the same optical channel can be achieved by combining melting curve analysis, and when the reaction system is applied to detection, the obtained melting curve peak shape is more stable than that of a conventional asymmetric PCR system, and the method is suitable for large-scale popularization and application. And the experiment repeatability and consistency are good.

The invention discloses a preparation method of an antibacterial coating material based on synergistic interaction of antibiotics and metal ions. The preparation method comprises the following steps: (1) blending antibiotics, soluble salts of metal ions, an absorbable polymer and a mixed solvent to obtain a coating solution; the antibiotics are selected from rifampicin and minocycline hydrochloride; the metal ions are selected from Zn and / or Cu; the mixed solvent is selected from hexafluoroisopropanol and a methanol / aqueous solution, and the volume ratio of hexafluoroisopropanol in the mixed solvent is not less than 25%; and (2) uniformly spraying the coating solution on the surface of the degradable base material through ultrasonic spraying, and then carrying out drying treatment. The preparation method is easy and convenient to operate, the obtained coating is tightly combined with a degradable base material, and the antibacterial rate can still reach 90% or above after 50 times of washing. According to the prepared antibacterial coating material, the synergistic release mode of rapid sterilization and long-acting bacteriostasis is achieved through raw material screening and process optimization, and the short-term and long-acting antibacterial performance can be remarkably improved.

The invention discloses a mycobacterium tuberculosis rpoB gene mutation detection method based on a CRISPR-Cas12a technology and a kit, and relates to the technical field of molecular biological detection. According to the present invention, through the design and the screening of the specific crRNA, the 531-crRNA4 with the nucleotide sequence represented by SEQ ID NO. 4 is successfully obtained; the sequence is combined with CRISPR-Cas12a and a PCR (Polymerase Chain Reaction) technology, can efficiently detect the rifampicin drug-resistant mutation site S531L, and has the remarkable advantages of high sensitivity, strong specificity, simplicity and convenience in operation and the like. The detection result of a clinical sample is highly consistent with the Sanger sequencing result, the detection time is shortened to be within 2 hours, and the method is suitable for rapid screening of clinical drug resistance. According to the technology, the time for doctors and patients to obtain detection reports is remarkably shortened, and the medical efficiency is effectively improved.

A technique of administering rifampicin over an extended period of time, with reduced side effects. A medicine that is for nasal administration and is used to prevent or treat neurodegenerative diseases, contains a rifampicin selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and a resveratrol selected from resveratrol and derivatives thereof, has reduced side effects, and can be administered over an extended period of time.

The present invention provides a novel pharmaceutical composition of polymyxin B / trimethoprim and rifampicin, as well as a preparation method and topical ocular application thereof (e.g., treatment of ocular infections).

An object of the present invention is to provide a drug that exhibits an action of inhibiting aggregation of a causative protein of an HRE-associated neurodegenerative disease such as ALS.SOLUTION: Rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof and / or resveratrols selected from the group consisting of resveratrol and derivatives thereof serve as an active ingredient of a prophylactic or therapeutic drug for a neurodegenerative disease caused by TDP-43 accumulation, or a prophylactic or therapeutic drug for ALS.SELECTED DRAWING: None

This invention discloses a method for introducing exogenous genes into Gynostemma pentaphyllum, comprising: S1: Selecting Gynostemma pentaphyllum seeds with seed coats within 3 months of harvest, disinfecting, and culturing to obtain aseptic seedlings from seedlings, or selecting stem segments with axillary buds after leaf removal, disinfecting, and culturing using a subculture proliferation medium containing cephalosporin to obtain aseptic rooted seedlings; S2: Selecting the aseptic seedlings or aseptic cuttings obtained in S1, culturing in a rooting medium containing cephalosporin to obtain aseptic rooted seedlings; S3: Transforming plasmid Pcambia1301-PMI into Agrobacterium and culturing in a medium containing kanamycin and rifampin to obtain an Agrobacterium resuspension; S4: Infecting the aseptic rooted seedlings obtained in S2 with the Agrobacterium resuspension, and performing co-culture, antibacterial culture, and screening culture to obtain transgenic adventitious shoots. This invention can successfully introduce exogenous genes into Gynostemma pentaphyllum, obtaining Gynostemma pentaphyllum positive plants.

The invention relates to the technical field of biology, in particular to bacteroides fragilis FMBL Ba24006 DMX for metabolism of pectic polysaccharides and application, the bacteroides fragilis FMBL Ba24006 DMX is preserved in China Center for Type Culture Collection on January 20, 2026, the preservation number is CCTCC M 2026175, the bacteroides fragilis FMBL Ba24006 DMX has good pectin metabolism capacity, pectin can be effectively used as a carbon source to achieve rapid proliferation, and meanwhile, the bacteroides fragilis FMBL Ba24006 DMX can be used for metabolism of pectic polysaccharides. The bacterial strain has a good antibacterial effect on hemorrhagic Escherichia coli; the compound is sensitive and moderately sensitive to cefoxitin and rifampicin. The strain can produce a large amount of short-chain fatty acid when being used for fermenting pectin, and fermentation liquor taking the pectin as a carbon source has relatively strong scavenging capacity on DPPH and ABTS free radicals; a relatively good inhibition effect is achieved on the activity of alpha-amylase; the method can be used for preparing antioxidant products, fermented foods, health-care products, food additives and feeds, and has a wide application prospect.

The invention discloses an intelligent double-response nanometer material artificial bone with a three-layer structure and a preparation method thereof, and relates to the technical field of medical materials, the intelligent double-response nanometer material artificial bone with the three-layer structure sequentially comprises a core support layer, an intelligent response drug layer and a surface bioactive coating from inside to outside; the core support layer contains 55-67 parts of polycaprolactone, 30-40 parts of alpha-tricalcium phosphate and 3-5 parts of magnesium hydroxide; the intelligent response drug layer is pH / temperature double-response nano-micelles loaded in pores of the core support layer and contains 95 to 105 parts of poly (2-(dimethylamino) ethyl methacrylate)-polyglutamic acid block copolymer, 5 to 8 parts of rifampicin and 0.1 to 0.3 part of anti-inflammatory factor; according to the invention, a three-layer composite structure is matched with precise components, so that degradation-regeneration matching and intelligent drug release are realized, a precise process is supplemented to guarantee stable performance, and the artificial bone repair efficiency and the mass production feasibility are improved.

The invention discloses a preparation method of an absorbable antibacterial coating material capable of slowly releasing antibiotics. The preparation method comprises the following steps: step 1, blending antibiotics, an absorbable polymer and a mixed solvent to obtain a coating solution; the antibiotics are selected from rifampicin and minocycline hydrochloride; the absorbable polymer is selected from one or more of polyglycolide, polylactide, polyglycolide-co-lactide, polyglycolide-co-caprolactone and tyrosine polyarylester; the absorbable polymer is selected from one or more of polyglycolide, polylactide, polyglycolide-co-lactide, polyglycolide-co-caprolactone and tyrosine polyarylester; the mixed solvent is selected from hexafluoroisopropanol and acetonitrile, and the volume ratio of the hexafluoroisopropanol in the mixed solvent is not less than 25%; and 2, uniformly spraying the coating solution on the surface of the degradable base material through ultrasonic spraying, and then carrying out drying treatment. According to the preparation method disclosed by the invention, the antibiotic, the absorbable polymer and the organic solvent are blended and dissolved and then are attached to the surface of the absorbable material through ultrasonic spraying, and the release of the antibiotic is regulated and controlled while the stability of the coating is ensured by regulating and controlling the ratio of the antibiotic to the polymer and the swelling characteristic of the solvent to the base material.

The application belongs to the technical field of biology and particularly relates to screening and application of a rifampicin-resistant tuberculosis urine metabolic marker. The urine metabolic marker comprises 20 metabolites. After verification, the level change of the 20 metabolites is indeed related to rifampicin-resistant tuberculosis. The application further provides a screening method of a rifampicin-resistant tuberculosis metabolic marker, a diagnostic rifampicin-resistant tuberculosis disease detection kit and a rifampicin-resistant tuberculosis disease diagnosis model. The 20 urine metabolic markers screened are used for rifampicin-resistant tuberculosis detection, have high accuracy and are of great significance for diagnosis of rifampicin-resistant tuberculosis.

The invention discloses a PCR-CRISPR method and a PCR-CRISPR system for integrated detection of drug-resistant sites of mycobacterium tuberculosis and rifampicin. Specifically, the invention discloses a PCR-CRISPR method for in-vitro non-diagnostic and non-therapeutic integrated detection of mycobacterium tuberculosis and rifampicin drug-resistant mutation sites, and the method comprises the following steps: (s1) providing a sample to be detected, and extracting total DNA; (s2) pushing nucleic acid liquid containing the total DNA into a first reaction chamber, and carrying out asymmetric PCR reaction to obtain a first fluorescence signal; (s3) pushing a PCR amplification product in the step (s2) into a second reaction chamber, carrying out CRISPR reaction in the second reaction chamber, and obtaining a second fluorescence signal for judging whether the target sequence exists or not; and (s4) combining and analyzing the first fluorescence signal and the second fluorescence signal to obtain a detection result of the mycobacterium tuberculosis and rifampicin drug-resistant mutation site. The method disclosed by the invention is high in detection sensitivity, convenient to operate and low in cost, and can be used for effectively screening tuberculosis and multidrug-resistant tuberculosis.

The invention belongs to the technical field of immunological detection, and particularly relates to a primer probe composition for detecting drug resistance of mycobacterium tuberculosis complex rifampicin and isoniazide and application of the primer probe composition. A multicolor melting curve method is adopted, rifampicin drug-resistant gene mutation detection is carried out by detecting mutation of drug-resistant determining regions of 507-533 sites of a mycobacterium tuberculosis complex rpoB gene, and isoniazide drug-resistant gene mutation detection is carried out by detecting mutation of ahpC promoter regions, inhA promoter regions and katG315 codons. The drug resistance condition of the detected strain can be judged according to the Tm value of the melting curve. The result of the embodiment shows that the rifampicin drug resistance detection and the isoniazide drug resistance detection realize the detection of mutation of one drug in one tube without separating two tubes, the drug resistance condition of one drug can be independently detected or the drug resistance conditions of two drugs can be detected by the two tubes together according to different conditions during use, the application is flexible, and the cost is low. The application market is wider.

The application discloses application of coumarin-polyethyleneimine fluorescent carbon dots in detection of antibiotic rifampicin. The fluorescent carbon dots have good selectivity, high sensitivity and strong anti-interference property as a probe. In a rifampicin concentration range of 0-25 muM, the change rate of carbon dot fluorescence has a linear relationship with the rifampicin concentration, and the detection limit is 0.67 muM. The fluorescent carbon dots are applied to detection of rifampicin in environmental water, the recovery rate is 95%-115%, the maximum relative standard deviation is 2.3%, and the fluorescent carbon dots have wide application prospects in the field of environmental monitoring. The fluorescent carbon dots are prepared into a portable paper-based sensor, and in a rifampicin concentration range of 0-90 muM, the RGB total value (R+G+B) captured by a mobile phone has a linear relationship with the rifampicin concentration. The paper-based sensor has low preparation cost, does not need large-scale instruments, and can realize in-situ and rapid visual detection of rifampicin by means of a smart phone software, so that the detection method is simple and efficient.

The application discloses application of rifampicin in preparation of a Myzus persicae insecticide.

The application belongs to the technical field of medicine, and discloses application of genistein in preparation of medicine for resisting Mycobacterium tuberculosis. The application discloses application of genistein or a pharmaceutically acceptable derivative thereof in inhibition of Mycobacterium tuberculosis or preparation of products for resisting Mycobacterium tuberculosis. Experiments show that the MIC of genistein to M. tb H37Rv ΔleuΔpan and M. tb M. tb M. tb M. tb M. tb H37Ra is 0.03 mg / mL, and under the action of 30 μg / mL genistein, the minimum inhibitory concentration of a rifampicin-resistant strain is reduced from 50 μg / mL to 6.25 μg / mL, which greatly improves the sensitivity of the drug-resistant strain to rifampicin. Therefore, genistein can be used in preparation of medicine for resisting Mycobacterium tuberculosis or resisting tuberculosis alone, and can also be used as an auxiliary medicine for other anti-tuberculosis medicines for combined use, that is, the types of anti-tuberculosis medicines are widened and the course of treatment of tuberculosis is expected to be shortened.

The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B / E, and pharmaceutically acceptable derivatives thereof; wherein the combination includes at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; provided the combination is not (1) polymyxin E / B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin. Also provided is an antimicrobial combination comprising three antimicrobial agents, wherein the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is zidovudine or a pharmaceutically acceptable derivative thereof; and the third antimicrobial agent is polymyxin E or a pharmaceutically acceptable derivative thereof.